Joachim Gullbo

Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

Huledal, Gunilla; Ruiz-Garcia, Ana; Kawakatsu, Sonoko; Wang, Xiaoning et al.

Ingår i Journal of clinical pharmacology, s. 240-252, 2024

• DOI för Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Byrgazov, Konstantin; Lind, Thomas; Rasmusson, Annica J.; Andersson, Claes et al.

Ingår i Bone Reports, 2021

• DOI för Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

Mateos, Maria-Victoria; Blade, Joan; Bringhen, Sara; Ocio, Enrique M. et al.

Ingår i Journal of Clinical Medicine, 2020

• DOI för Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma
• Ladda ner fulltext (pdf) av Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

Melflufen for relapsed and refractory multiple myeloma

Oriol, Albert; Larocca, Alessandra; Leleu, Xavier; Hajek, Roman et al.

Ingår i Expert Opinion on Investigational Drugs, s. 1069-1078, 2020

• DOI för Melflufen for relapsed and refractory multiple myeloma

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

Mofers, Arjan; Perego, Paola; Selvaraju, Karthik; Gatti, Laura et al.

Ingår i PLOS ONE, 2019

• DOI för Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15
• Ladda ner fulltext (pdf) av Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

Huledal, Gunilla; Ruiz-Garcia, Ana; Kawakatsu, Sonoko; Wang, Xiaoning et al.

Ingår i Journal of clinical pharmacology, s. 240-252, 2024

• DOI för Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Byrgazov, Konstantin; Lind, Thomas; Rasmusson, Annica J.; Andersson, Claes et al.

Ingår i Bone Reports, 2021

• DOI för Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Melflufen for relapsed and refractory multiple myeloma

Oriol, Albert; Larocca, Alessandra; Leleu, Xavier; Hajek, Roman et al.

Ingår i Expert Opinion on Investigational Drugs, s. 1069-1078, 2020

• DOI för Melflufen for relapsed and refractory multiple myeloma

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

Mofers, Arjan; Perego, Paola; Selvaraju, Karthik; Gatti, Laura et al.

Ingår i PLOS ONE, 2019

• DOI för Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15
• Ladda ner fulltext (pdf) av Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Mody, Kabir; Mansfield, Aaron S.; Vemireddy, Lalitha; Nygren, Peter et al.

Ingår i Investigational new drugs, s. 684-692, 2019

• DOI för A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Eriksson, Anna; Chantzi, Efthymia; Fryknäs, Mårten; Gullbo, Joachim et al.

Ingår i Leukemia Research, s. 41-46, 2017

• DOI för Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
• Ladda ner fulltext (pdf) av Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

Karlsson, Henning; Fryknäs, Mårten; Strese, Sara; Gullbo, Joachim et al.

Ingår i Oncotarget, s. 30217-30234, 2017

• DOI för Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
• Ladda ner fulltext (pdf) av Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia

Strese, Sara; Hassan, Saadia Bashir; Velander, Ebba; Haglund, Caroline et al.

Ingår i Oncotarget, s. 6341-6352, 2017

• DOI för In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia

Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma

Delforoush, Maryam; Berglund, Mattias; Edqvist, Per-Henrik; Sundström, Christer et al.

Ingår i European Journal of Haematology, s. 52-56, 2017

• DOI för Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma

Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study

Lindman, Henrik; Nilsson, A.; Gullbo, Joachim

Ingår i Cancer Research, 2017

• DOI för Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study

In vitro and in vivo activity of melflufen (J1) in lymphoma

Delforoush, Maryam; Strese, Sara; Wickström, Malin; Larsson, Rolf et al.

Ingår i BMC Cancer, 2016

• DOI för In vitro and in vivo activity of melflufen (J1) in lymphoma

Preclinical activity of melflufen (J1) in ovarian cancer

Carlier, Charlotte; Strese, Sara; Viktorsson, Kristina; Velander, Ebba et al.

Ingår i Oncotarget, s. 59322-59335, 2016

• DOI för Preclinical activity of melflufen (J1) in ovarian cancer

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

Ray, Arghya; Ravillah, Durgadevi; Das, Deepika S.; Song, Yan et al.

Ingår i British Journal of Haematology, s. 397-409, 2016

• DOI för A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

Wang, Xin; Mazurkiewicz, Magdalena; Hillert, Ellin-Kristina; Olofsson, Maria Hagg et al.

Ingår i Scientific Reports, 2016

• DOI för The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
• Ladda ner fulltext (pdf) av The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

Iron chelators target both proliferating and quiescent cancer cells

Fryknäs, Mårten; Zhang, Xiaonan; Bremberg, Ulf; Senkowski, Wojciech et al.

Ingår i Scientific Reports, 2016

• DOI för Iron chelators target both proliferating and quiescent cancer cells
• Ladda ner fulltext (pdf) av Iron chelators target both proliferating and quiescent cancer cells

Repositioning Of Quinacrine For Treatment Of Acute Myeloid Leukemia - Synergies And In Vivo Effects

Eriksson, Anna; Gustafsson, Mats; Fryknäs, Mårten; Gullbo, Joachim et al.

Ingår i Haematologica, s. 367-368, 2016

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Mohell, N.; Alfredsson, J.; Fransson, A.; Uustalu, M. et al.

Ingår i Cell Death and Disease, 2015

• DOI för APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
• Ladda ner fulltext (pdf) av APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

Eriksson, Anna; Österroos, Albin; Hassan, Sadia Bashir; Gullbo, Joachim et al.

Ingår i Blood Cancer Journal, 2015

• DOI för Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
• Ladda ner fulltext (pdf) av Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

Design, synthesis and biological evaluation of Novel Curcumin Analogs with anticipated anticancer activity

Fawzy, Iten M.; Youssef, Khairia M.; Ismail, Nasser S. M.; Gullbo, Joachim et al.

Ingår i FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, s. 22-31, 2015

• DOI för Design, synthesis and biological evaluation of Novel Curcumin Analogs with anticipated anticancer activity

FGF2 as a potential prognostic biomarker for proneural glioma patients

Sooman, Linda; Freyhult, Eva; Jaiswal, Archita; Navani, Sanjay et al.

Ingår i Acta Oncologica, s. 385-394, 2015

• DOI för FGF2 as a potential prognostic biomarker for proneural glioma patients

Newly Designed and Synthesized Curcumin Analogs with in vitro Cytotoxicity and Tubulin Polymerization Activity

Fawzy, Iten M.; Youssef, Khairia M.; Ismail, Nasser S. M.; Gullbo, Joachim et al.

Ingår i Chemical Biology and Drug Design, s. 860-870, 2015

• DOI för Newly Designed and Synthesized Curcumin Analogs with in vitro Cytotoxicity and Tubulin Polymerization Activity

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Åke; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey et al.

Ingår i Investigational new drugs, s. 1232-1241, 2015

• DOI för First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

Wang, Xin; D'Arcy, Padraig; Caulfield, Thomas R.; Paulus, Aneel et al.

Ingår i Chemical Biology and Drug Design, s. 1036-1048, 2015

• DOI för Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Paulus, Aneel; Akhtar, Sharoon; Samuel, Kelara; Yousaf, Hassan et al.

Ingår i Blood, 2015

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Paulus, Aneel; Akhtar, Sharoon; Samuel, Kelara; Yousaf, Hassan et al.

Ingår i Blood, 2015

The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death

Wang, Xin; Stafford, William; Mazurkiewicz, Magdalena; Fryknäs, Mårten et al.

Ingår i Molecular Pharmacology, s. 932-945, 2014

• DOI för The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Zhang, Xiaonan; Fryknäs, Mårten; Hernlund, Emma; Fayad, Walid et al.

Ingår i Nature Communications, s. 3295, 2014

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Zhang, Xiaonan; Fryknäs, Mårten; Hernlund, Emma; Fayad, Walid et al.

Ingår i Nature Communications, s. 3295, 2014

• DOI för Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
• Ladda ner fulltext (pdf) av Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas

Sooman, Linda; Ekman, Simon; Tsakonas, Georgios; Jaiswal, Archita et al.

Ingår i Tumor Biology, s. 4479-4488, 2014

• DOI för PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas

Repositioning of Quinacrine for Treatment of Acute Myeloid Leukemia

Eriksson, Anna; Osterros, Albin; Hassan, Sadia Bashir; Gullbo, Joachim et al.

Ingår i Blood, 2014

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Fryknäs, Mårten; Gullbo, Joachim; Wang, Xin; Rickardson, Linda et al.

Ingår i BMC Cancer, s. 374, 2013

• DOI för Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
• Ladda ner fulltext (pdf) av Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Effects of hypoxia on human cancer cell line chemosensitivity

Strese, Sara; Fryknäs, Mårten; Larsson, Rolf; Gullbo, Joachim

Ingår i BMC Cancer, s. 331, 2013

• DOI för Effects of hypoxia on human cancer cell line chemosensitivity
• Ladda ner fulltext (pdf) av Effects of hypoxia on human cancer cell line chemosensitivity

Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival

Sooman, Linda; Lennartsson, Johan; Gullbo, Joachim; Bergqvist, Michael et al.

Ingår i Medical Oncology, s. 638, 2013

• DOI för Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival

Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells

Wu, Xuping; Sooman, Linda; Lennartsson, Johan; Bergström, Stefan et al.

Ingår i International Journal of Oncology, s. 297-304, 2013

• DOI för Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells

Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines

Sooman, Linda; Ekman, Simon; Andersson, Claes; Kultima, Hanna Göransson et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 329-340, 2013

• DOI för Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines

Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system

Felth, Jenny; Lesiak-Mieczkowska, Karolina; Haglund, Caroline; Gullbo, Joachim et al.

Ingår i Investigational new drugs, s. 587-598, 2013

• DOI för Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system

The Nanoparticulate Quillaja Saponin BBE Is Selectively Active Towards Renal Cell Carcinoma

Hassan, Saadia Bashir; Gullbo, Joachim; Hu, Kefei; Berenjian, Saideh et al.

Ingår i Anticancer Research, s. 143-151, 2013

The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: Discovery of an active cardiac glycoside from Urginea maritima

El-Seedi, Hesham R.; Burman, Robert; Mansour, Ahmed; Turki, Zaki et al.

Ingår i Journal of Ethnopharmacology, s. 746-757, 2013

• DOI för The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: Discovery of an active cardiac glycoside from Urginea maritima

Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Jarvius, Malin; Fryknäs, Mårten; D'Arcy, Padraig; Sun, Chao et al.

Ingår i Biochemical and Biophysical Research Communications - BBRC, s. 117-123, 2013

• DOI för Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro

Wu, Xuping; Sooman, Linda; Wickström, Malin; Fryknäs, Mårten et al.

Ingår i Molecular Cancer Therapeutics, s. 1526-1536, 2013

• DOI för Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro

The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo

Strese, Sara; Wickström, Malin; Fuchs, Peder Fredlund; Fryknäs, Mårten et al.

Ingår i Biochemical Pharmacology, s. 888-895, 2013

• DOI för The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo

Synergistic Effects of PI3K or P38 MAPK Inhibition in Combination With Vandetanib Treatment in Glioblastoma Cells

Sooman, Linda; Ekman, Simon; Andersson, Claes; Johansson, Fredrik et al.

Ingår i European Journal of Cancer, 2012

• DOI för Synergistic Effects of PI3K or P38 MAPK Inhibition in Combination With Vandetanib Treatment in Glioblastoma Cells

Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity

Wu, Xuping; Hedman, Håkan; Bergqvist, Michael; Bergström, Stefan et al.

Ingår i Acta Oncologica, s. 69-76, 2012

• DOI för Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Haglund, Caroline; Åleskog, Anna; Nygren, Peter; Gullbo, Joachim et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 697-707, 2012

• DOI för In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

SHP1 expression is epigenetically regulated and influences the sensitivity to chemotherapeutic agents in glioblastoma cells

Sooman, Linda; Ekman, S.; Bergqvist, Michael; Gullbo, Joachim et al.

Ingår i Neuro-Oncology, 2012

• DOI för SHP1 expression is epigenetically regulated and influences the sensitivity to chemotherapeutic agents in glioblastoma cells

Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents

Dyrager, Christine; Wickström, Malin; Fridén-Saxin, Maria; Friberg, Annika et al.

Ingår i Bioorganic & Medicinal Chemistry, s. 2659-2665, 2011

• DOI för Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents

Cytotoxic potency of small macrocyclic knot proteins: Structure-activity and mechanistic studies of native and chemically modified cyclotides

Burman, Robert; Herrmann, Anders; Tran, Rosetti; Kivelä, Jan-Erik et al.

Ingår i Organic and biomolecular chemistry, s. 4306-4314, 2011

• DOI för Cytotoxic potency of small macrocyclic knot proteins: Structure-activity and mechanistic studies of native and chemically modified cyclotides

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

Gullbo, Joachim; Fryknäs, Mårten; Rickardson, Linda; Darcy, Padraig et al.

Ingår i Biochemical Pharmacology, s. 139-147, 2011

• DOI för Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia

Hallböök, Helene; Felth, Jenny; Eriksson, Anna; Fryknäs, Mårten et al.

Ingår i PLOS ONE, 2011

• DOI för Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia

Novel activity of acriflavine against colorectal cancer tumor cells

Hassan, Saadia; Laryea, Daniel; Mahteme, Haile; Felth, Jenny et al.

Ingår i Cancer Science, s. 2206-2213, 2011

• DOI för Novel activity of acriflavine against colorectal cancer tumor cells

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index

Hu, Kefei; Berenjian, Saideh; Larsson, Rolf; Gullbo, Joachim et al.

Ingår i International Journal of Nanomedicine, s. 51-62, 2010

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan

Wickström, Malin; Viktorsson, Kristina; Lundholm, Lovisa; Aesoy, Reidun et al.

Ingår i Biochemical Pharmacology, s. 1281-1290, 2010

• DOI för The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan

Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Laryea, Daniel; Gullbo, Joachim; Isaksson, Anders; Larsson, Rolf et al.

Ingår i Anti-Cancer Drugs, s. 33-42, 2010

• DOI för Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Synthesis and Characterization of a Multi Ring-Fused 2-Pyridone-Based Fluorescent Scaffold

Sellstedt, Magnus; Nyberg, Anders; Rosenbaum, Erik; Engström, Patrik et al.

Ingår i European Journal of Organic Chemistry, s. 6171-6178, 2010

• DOI för Synthesis and Characterization of a Multi Ring-Fused 2-Pyridone-Based Fluorescent Scaffold

Evaluation of toxicity and anti-tumour activity of cycloviolacin O2 in mice.

Burman, Robert; Svedlund, Erika; Felth, Jenny; Hassan, Saadia et al.

Ingår i Biopolymers, s. 626-634, 2010

• DOI för Evaluation of toxicity and anti-tumour activity of cycloviolacin O2 in mice.

ChemGPS-NP mapping of chemical compounds for prediction of anticancer mode of action

Rosén, Josefin; Rickardson, Linda; Backlund, Anders; Gullbo, Joachim et al.

Ingår i QSAR & combinatorial science (Print), s. 436-446, 2009

• DOI för ChemGPS-NP mapping of chemical compounds for prediction of anticancer mode of action

Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug

Lövborg, Henrik; Burman, Robert; Gullbo, Joachim

Ingår i BMC research notes, s. 114, 2009

• DOI för Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug

Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs

Felth, Jenny; Rickardson, Linda; Rosén, Josefin; Wickström, Malin et al.

Ingår i Journal of natural products (Print), s. 1969-1974, 2009

• DOI för Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

Wu, Xuping; Wanders, Alkwin; Wardega, Piotr; Tinge, B. et al.

Ingår i British Journal of Cancer, s. 334-343, 2009

• DOI för Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

The alpine violet, Viola biflora, is a rich source of novel cyclotides with potent cytotoxic cytotoxicity

Herrmann, Anders; Burman, Robert; Mylne, Joshua S.; Karlsson, Gustav et al.

Ingår i Phytochemistry, s. 939-952, 2008

• DOI för The alpine violet, Viola biflora, is a rich source of novel cyclotides with potent cytotoxic cytotoxicity

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

Wickström, Malin; Haglund, Caroline; Lindman, Henrik; Nygren, Peter et al.

Ingår i Investigational new drugs, s. 195-204, 2008

• DOI för The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma

Berglund, Mattias; Thunberg, Ulf; Fridberg, Marie; Wingren, Anette Gjörloff et al.

Ingår i Leukemia and Lymphoma, s. 1038-1041, 2007

• DOI för Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma

Mechanism of action of cytotoxic cyclotides: cycloviolacin O2 disrupts lipid membranes

Svangård, Erika; Burman, Robert; Gunasekera, Sunithi; Lövborg, Henrik et al.

Ingår i Journal of natural products (Print), s. 643-647, 2007

• DOI för Mechanism of action of cytotoxic cyclotides: cycloviolacin O2 disrupts lipid membranes

The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

Wickström, Malin; Johnsen, John Inge; Ponthan, Frida; Segerström, Lova et al.

Ingår i Molecular Cancer Therapeutics, s. 2409-2417, 2007

• DOI för The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

Wickström, Malin; Danielsson, Katarina; Rickardson, Linda; Gullbo, Joachim et al.

Ingår i Biochemical Pharmacology, s. 25-33, 2007

• DOI för Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram

Lövborg, Henrik; Öberg, Fredrik; Rickardson, Linda; Gullbo, Joachim et al.

Ingår i International Journal of Cancer, s. 1577-1580, 2006

• DOI för Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram

Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

Fryknäs, Mårten; Rickardson, Linda; Wickström, Malin; Dhar, Sumeer et al.

Ingår i Journal of Biomolecular Screening, s. 457-468, 2006

• DOI för Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

Peracid dependent stereoselectivity and functional group contribution to the stereocontrol of epoxidation of (E)-alkene dipeptide isosteres

Wiktelius, Daniel; Berts, Wei; Jenmalm Jensen, Annika; Gullbo, Joachim et al.

Ingår i Tetrahedron, s. 3600-3609, 2006

Future Prospects for Old Chemotherapeutic Drugs in the Target-Specific Era; Pharmaceutics, Combinations, Co-Drugs and Prodrugs with Melphalan as an Example

Wickström, Malin; Lövborg, Henrik; Gullbo, Joachim

Ingår i Letters in Drug Design & Discovery, s. 695-703, 2006

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles

Rickardson, Linda; Fryknäs, Mårten; Dhar, Sumeer; Lövborg, Henrik et al.

Ingår i British Journal of Cancer, s. 483-492, 2005

Screening for apoptosis--classical and emerging techniques.

Lövborg, Henrik; Gullbo, Joachim; Larsson, Rolf

Ingår i Anticancer Drugs, s. 593-9, 2005

Cytotoxic cyclotides from Viola tricolor

Svangård, Erika; Göransson, Ulf; Hocaoglu, Zozan; Gullbo, Joachim et al.

Ingår i Journal of natural products (Print), s. 144-7, 2004

• DOI för Cytotoxic cyclotides from Viola tricolor

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Gullbo, Joachim; Lindhagen, Elin; Bashir-Hassan, Saadia; Tullberg, Marcus et al.

Ingår i Invest New Drugs, s. 411-20, 2004

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguadine CHS 828

Gullbo, Joachim; Lövborg, Henrik; Dhar, Sumeer; Lukinius, Agneta et al.

Ingår i Anti-Cancer Drugs, s. 45-54, 2004

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1

Gullbo, Joachim; Wickström, Malin; Tullberg, Marcus; Ehrsson, Hans et al.

Ingår i Journal of drug targeting (Print), s. 355-363, 2003

• DOI för Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1

Structure activity relationship for alkylating dipeptide nitrogen mustard derivatives

Gullbo, Joachim; Tullberg, Marcus; Våbeno, Jon; Ehrsson, Hans et al.

Ingår i Oncology Research, s. 113-132, 2003

Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-melphalanyl-p-L-fluorophenylalanine ethyl ester): Comparison with its m-L-sarcolysin analogue P2

Gullbo, Joachim; Wallinder, Charlotta; Tullberg, Marcus; Lövborg, Henrik et al.

Ingår i Molecular Cancer Therapeutics, s. 1331-1339, 2003

Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells

Johansson, S.; Gullbo, Joachim; Lindholm, P.; Ek, B. et al.

Ingår i Cellular and Molecular Life Sciences (CMLS), s. 165-175, 2003

• DOI för Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells

p53 status and its in vitro relationship to radiosensitivity andchemosensitivity in lung cancer.

Bergqvist, Michael; Brattstrom, Daniel; Gullbo, Joachim; Hesselius, Patrik et al.

Ingår i Anticancer Res, s. 1207, 2003

Antitumor activity of the alkylating oligopeptides J1(L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2(L-prolyl-m-L-fluorophenylalanine ethyl ester):comparison with melphalan.

Gullbo, Joachim; Dhar, Sumeer; Luthman, K; Ehrsson, H et al.

Ingår i Anticancer Drugs., s. 617, 2003

Cyclotides: a novel type of cytotoxic agents

Lindholm, Petra; Göransson, Ulf; Johansson, Senia; Claeson, Per et al.

Ingår i Molecular Cancer Therapeutics, s. 365-369, 2002

Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga

Li, Shi-Sheng; Gullbo, Joachim; Lindholm, Petra; Larsson, Rolf et al.

Ingår i Biochemical Journal, s. 405-13, 2002

• DOI för Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga

Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.

Lövborg, Henrik; Martinsson, Petra; Gullbo, Joachim; Ekelund, Sara et al.

Ingår i Biochem Pharmacol, s. 1491, 2002

Cytotoxic activity of a new lipid formulation of doxorubicin in cell lines and primary tumor cells.

Gullbo, Joachim; Arsenau, D; Grundmark, Birgitta; Alvfors, Carina et al.

Ingår i Anticancer Res, s. 4191, 2002

Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells

Johansson, Senia; Lindholm, Petra; Gullbo, Joachim; Larsson, Rolf et al.

Ingår i Anti-Cancer Drugs, s. 475-83, 2001

Antitumor effect of suramin analogues in human tumour cell lines and primary cultures of tumour cells

Dhar, Sumeer; Gullbo, Joachim; Csoka, Katalin; Eriksson, E et al.

Ingår i Eur J Cancer, s. 803, 2000

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

Mateos, Maria-Victoria; Blade, Joan; Bringhen, Sara; Ocio, Enrique M. et al.

Ingår i Journal of Clinical Medicine, 2020

• DOI för Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma
• Ladda ner fulltext (pdf) av Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

Melflufen: a peptidase-potentiated alkylating agent in clinical trials

Wickström, Malin; Nygren, Peter; Larsson, Rolf; Harmenberg, Johan et al.

Ingår i Oncotarget, s. 66641-66655, 2017

• DOI för Melflufen: a peptidase-potentiated alkylating agent in clinical trials
• Ladda ner fulltext (pdf) av Melflufen: a peptidase-potentiated alkylating agent in clinical trials

Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics

Zhang, Xiaonan; De Milito, Angelo; Demiroglu-Zergeroglu, Asuman; Gullbo, Joachim et al.

Ingår i Trends in Cancer, s. 657-663, 2016

• DOI för Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics

Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors

Zhang, Xiaonan; de Milito, Angelo; Olofsson, Maria Hagg; Gullbo, Joachim et al.

Ingår i International Journal of Molecular Sciences, s. 27313-27326, 2015

Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors

Zhang, Xiaonan; de Milito, Angelo; Olofsson, Maria Hagg; Gullbo, Joachim et al.

Ingår i International Journal of Molecular Sciences, s. 27313-27326, 2015

• DOI för Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors
• Ladda ner fulltext (pdf) av Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors

Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

Selvaraju, Karthik; Mazurkiewicz, Magdalena; Wang, Xin; Gullbo, Joachim et al.

Ingår i Drug resistance updates, s. 20-29, 2015

• DOI för Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

Aminopeptidase N (CD13) as a target for cancer chemotherapy

Wickström, Malin; Larsson, Rolf; Nygren, Peter; Gullbo, Joachim

Ingår i Cancer Science, s. 501-508, 2011

• DOI för Aminopeptidase N (CD13) as a target for cancer chemotherapy

Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies

Ekman, Simon; Eriksson, Peter; Bergström, Stefan; Johansson, Peter et al.

Ingår i Anticancer Research, s. 3545-3553, 2007

Inhibition of the 19 S proteasome by bAP-15 in lymphoma cell lines

Delforoush, Maryam; Sun, Chao; Thomas, Strömberg; Strese, Sara et al.